MK0429

Phase 2Small molecule

Merck & Co.

MK0429 is one of 7 small molecule programs targeting Bone Resorption. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone ResorptionActive, not recruiting

Bone ResorptionPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Bone Resorption

#DrugCompanyPhaseTrials

Fosamax

OOrganon and Co

Approved

1 2

Zometa

Pfizer

Phase 3

1 3

Prolia

Amgen

Preclinical

1 4

Platelet Rich Plasma

ZZagazig University

Phase 1

1 5

Humira

CCelltrion

Preclinical

2 6

MK0429

Merck & Co.

Phase 2

1 7

Veverimer

RRenibus Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Resorption1 trial

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00533650·227 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MK0429. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK0429 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK0429. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

MK0429

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Resorption1 trial

References

Drug Info

Quick Facts

Related News